ArticleScientific reports2016
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 140 citations in OpenAlex.
- Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening.Journal of biological engineering · 2025Review
- Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control.Mathematical biosciences · 2025Article
- Multiscale mathematical model-informed reinforcement learning optimizes combination treatment scheduling in glioblastoma evolution.Science advances · 2025Article
- Modeling critical dosing strategies for stromal-induced resistance to cancer therapy.NPJ systems biology and applications · 2025Article
- Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers.NPJ precision oncology · 2024Article
- A comprehensive review of computational cell cycle models in guiding cancer treatment strategies.NPJ systems biology and applications · 2024Review
- Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.NPJ systems biology and applications · 2024Article
- A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models.Scientific reports · 2023Article
- Mathematical model combined with microdosimetric kinetic model for tumor volume calculation in stereotactic body radiation therapy.Scientific reports · 2023Article
- Multicomponent mathematical model for tumor volume calculation with setup error using single-isocenter stereotactic radiotherapy for multiple brain metastases.Physical and engineering sciences in medicine · 2023Article
- Tumor organoid biobank-new platform for medical research.Scientific reports · 2023Article
- Multiscale modeling of drug resistance in glioblastoma with gene mutations and angiogenesis.Computational and structural biotechnology journal · 2023Article
- Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation.Molecular cancer therapeutics · 2022Article
- Functional stratification of cancer drugs through integrated network similarity.NPJ systems biology and applications · 2022Article
- Optimizing Dosage-Specific Treatments in a Multi-Scale Model of a Tumor Growth.Frontiers in molecular biosciences · 2022Article
- Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin.Frontiers in molecular biosciences · 2022Article
- Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids.Frontiers in pharmacology · 2022Article
- Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival.Cancer drug resistance (Alhambra, Calif.) · 2022Article
- Cancer nanotechnology: current status and perspectives.Nano convergence · 2021Review
- Epigenetic instability may alter cell state transitions and anticancer drug resistance.PLoS computational biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Drug resistance significantly limits the long-term effectiveness of targeted therapeutics for cancer patients. Recent experimental studies have demonstrated that cancer cell heterogeneity and microenvironment adaptations to targeted therapy play important roles in promoting the rapid acquisition of drug resistance and in increasing cancer metastasis. The systematic development of effective therapeutics to overcome drug resistance mechanisms poses a major challenge. In this study, we used a modeling approach to connect cellular mechanisms underlying cancer drug resistance to population-level patient survival. To predict progression-free survival in cancer patients with metastatic melanoma, we developed a set of stochastic differential equations to describe the dynamics of heterogeneous cell populations while taking into account micro-environment adaptations. Clinical data on survival and circulating tumor cell DNA (ctDNA) concentrations were used to confirm the effectiveness of our model. Moreover, our model predicted distinct patterns of dose-dependent synergy when evaluating a combination of BRAF and MEK inhibitors versus a combination of BRAF and PI3K inhibitors. These predictions were consistent with the findings in previously reported studies. The impact of the drug metabolism rate on patient survival was also discussed. The proposed model might facilitate the quantitative evaluation and optimization of combination therapeutics and cancer clinical trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.